The Longevity Fund_Arts & Entertainment

FAQ FAQ Scroll Investing in Human Longevity.We back world class entrepreneurs developing therapeutic breakthroughs for age-related disease. Lifespan and aging is malleable. The scientific pathways behind this effect are incredibly complex and difficult to correctly control, but manipulating them may lead to new treatments for age-related disease. We want to get these therapeutic advances translated safely to patients as quickly as possible. Longevity Fund companies have collected >$1B in follow-on funding, with 5 IPOs, and multiple programs in the clinic to reverse or prevent age-related disease.Some of the companies we have backed:ALX ONCOLOGY - Immuno-oncology drugs. (IPO 2020)LOYAL - Dog lifespan extension.DECIBEL THERAPEUTICS - Therapeutics for age-related hearing loss. (IPO 2021)EPIRIUM BIO - Mitochondrial biogenesis.FAUNA BIO - Drug discovery informed by hibernating mammals.GORDIAN BIOTECHNOLOGY - Multi-modal gene therapy for aging. METACRINE - Farnesoid drug development. (IPO 2020)NAVITOR PHARMACEUTICALS - mTOR modifiers.PRECISION BIOSCIENCES - Gene editing. (IPO 2019)SPRING DISCOVERY - ML aging drug discovery.SYSTEM1 BIOSCIENCES - Brain-organoid drug discovery. UNITY BIOTECHNOLOGY - Senolytics to increase healthspan. (IPO 2018)What We DoVenture InvestingWe invest in Seed and Series A companies developing drugs for aging and age-related diseases. We can lead and follow rounds. FAQ here. Company BuildingFounder-friendly company incubation. Activation & EducationFinding and supporting the next generation of biotech founders.Select Writing Applying Tech Frameworks to Biotech: Key Differences | Celine HaliouaLongevity FAQ | Laura DemingAdvice for Ambitious Teenagers | Laura DemingSequencing is the New Microscope | Laura DemingWorking on Aging in the Time of COVID-19 | Celine HaliouaWhy I Care About Longevity | Celine HaliouaWho We Are // Laura Deming (GENERAL PARTNER & FOUNDER) + Celine Halioua (Venture Partner)Contact // [email protected] —> straight to GP inbox About